23andMe has licensed an antibody it developed from its genetic database to treat inflammatory diseases to Spanish drugmaker Almirall SA. "The deal, announced by Almirall in a filing with Spanish regulators on Thursday, marks the first time that 23andMe has licensed a drug compound that it has developed itself," reports Bloomberg. From the report: